循环肿瘤DNA分析显示多发性骨髓瘤空间突变异质性与疾病复发一致
研究评估血浆游离肿瘤DNA(ctDNA)作为骨髓活检辅助手段,对33例复发/难治和15例新诊断多发性骨髓瘤患者进行KRAS、NRAS、BRAF和TP53突变检测。结果显示血浆突变占54%,复发/难治患者血浆独有突变频率高于新诊断患者(27.2% vs 6.6%),69%患者携带至少一种RAS突变。连续ctDNA定量可反映疾病状态变化。
要点
- ctDNA分析可检测骨髓活检未捕获的血浆独有突变,提示空间遗传异质性。
- 复发/难治患者血浆独有突变频率高于新诊断患者(27.2% vs 6.6%)。
- 69%患者携带至少一种RAS激活突变,高于既往报道。
核心结论
- ctDNA分析作为骨髓活检的辅助手段,是一种无创且全面的策略,可用于改善多发性骨髓瘤的突变特征描述和治疗监测。
研究设计与样本
- 研究纳入33例复发/难治和15例新诊断多发性骨髓瘤患者,配对分析骨髓骨髓瘤细胞DNA和血浆ctDNA,使用OnTarget Mutation Detection(OMD)平台检测KRAS、NRAS、BRAF和TP53突变。
- 对7例患者通过纵向血浆追踪特定克隆,使用微滴数字PCR进行连续ctDNA定量。
主要发现
- OMD共检测到128个突变(血浆31个,骨髓59个,两者均阳性38个),表明血浆突变存在率为54%。
- 复发/难治患者血浆独有突变频率高于新诊断患者(27.2% vs 6.6%)。
- 69%的患者携带至少一种RAS突变。
- 7例患者的连续ctDNA定量显示特定克隆的分数丰度变化反映疾病状态。
临床怎么用
- 作者认为ctDNA分析作为骨髓活检的辅助手段,可用于改善多发性骨髓瘤的突变特征描述和治疗监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mutational characterisation in multiple myeloma (MM) currently relies on bone marrow (BM) biopsy, which fails to capture the putative spatial and genetic heterogeneity of this multifocal disease. Analysis of plasma (PL)-derived circulating free tumour DNA (ctDNA) as an adjunct to BM biopsy, for mutational characterisation and tracking disease progression, was evaluated. Paired BM MM cell DNA and ctDNA from 33 relapsed/refractory (RR) and 15 newly diagnosed (ND) patients were analysed for KRAS, NRAS, BRAF and TP53 mutations using the OnTarget Mutation Detection (OMD) platform. OMD detected 128 mutations (PL=31, BM=59, both=38) indicating the presence of PL mutations (54%). A higher frequency of PL-only mutations was detected in RR patients than ND (27.2% vs 6.6%, respectively), authenticating the existence of spatial and genetic heterogeneity in advanced disease. Activating RAS mutations were more highly prevalent than previously described with 69% harboring at least one RAS mutation. Sequential ctDNA quantitation with droplet digital PCR through longitudinal PL tracking of specific clones in seven patients demonstrated changes in fractional abundance of certain clones reflective of the disease status. We conclude that ctDNA analysis as an adjunct to BM biopsy represents a noninvasive and holistic strategy for improved mutational characterisation and therapeutic monitoring of MM.
引用
- Mithraprabhu S, Khong T, Ramachandran M, et al. Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma. Leukemia. 2016. PMID: 27899805. doi:10.1038/leu.2016.366
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。